Pacifico Biolabs announced that it has raised €7 million in Series A funding to accelerate the scale-up of its mycelium protein production platform and support its commercial launch. The company’s approach leverages existing brewery infrastructure to produce alternative proteins, creating a capital-efficient pathway to expand sustainable food production.
The funding round was backed by Stray Dog Capital, TGFS Technologiegründerfonds Sachsen, Sprout & About Ventures, Simon Capital, FoodLabs, and a regional brewery partner. The investors are supporting Pacifico Biolabs’ vision that combining European industrial infrastructure with modern biotechnology can help shape the next generation of protein production.
With the new capital, Pacifico Biolabs plans to increase production capacity, grow its team, and advance commercialization efforts. The company expects to bring its products to retail shelves by late 2026 as it continues expanding its operations and market presence.
KEY QUOTES:
“Thank you to our investors Stray Dog Capital, TGFS Technologiegründerfonds Sachsen, Sprout & About Ventures, Simon Capital, FoodLabs, and our regional brewery partner for sharing our conviction that together, European infrastructure and modern biotechnology will define the next generation of protein.”
“In this next chapter, we will scale production, expand our team, and bring products to retail shelves by late 2026.”
Pacifico Biolabs
